Abstracts Archive - Page 435 of 2425 - ACR Meeting Abstracts

Abstract Number: 2265 • ACR Convergence 2022
Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Henri Tiedge¹, ILHAM MUSLIMOV², Valerio Berardi², Stacy Stephenson³, Ellen M. Ginzler⁴, Anca Askanase⁵ and John Hanly⁶, ¹SUNY, Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, NY, ³SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, ⁴SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 2206 • ACR Convergence 2022
Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder¹, Fangya Ma², Josefina Marin³, Minna Kohler⁴, Janeth Yinh⁵, Ari Polachek⁶, Marcos Rosemffet⁷, Ernesto Rodriguez⁸, Ilaria Tinnazzi⁹, Amir Haddad¹⁰, Philippe Carron¹¹, Mariana Alves Ferreira Martins¹², Catherine Bakewell¹³, Fahmeen J. Afgani¹⁴, Richard Cook², Sibel Aydin¹⁵ and Gurjit S. Kaeley¹⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Tel Aviv Medical Center, Tel Aviv, Israel, ⁷Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁸Florida Medical Clinic, Tampa, FL, ⁹Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, ¹⁰Carmel Medical Centre, Haifa, Israel, ¹¹Ghent University Hospital, Ghent, Belgium, ¹²São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, ¹³Intermountain Healthcare, Salt Lake City, UT, ¹⁴Women's College Hospital, Toronto, ON, Canada, ¹⁵University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ¹⁶UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…
Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 2033 • ACR Convergence 2022
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 1672 • ACR Convergence 2022
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Andrea Lojacono², Francesca Ramazzotto³, Cristina Zanardini³, Zatti Sonia³, Angela Tincani⁴, Franco Franceschini¹, Paolo Airò⁵ and Laura Andreoli¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, ³Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 1886 • ACR Convergence 2022
Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up
David Martínez-López¹, Piotr Szczęsny², Inger Nennesmo³, Karina Gheorghe⁴, Antonella Notarnicola⁵, Helene Alexanderson⁶, Ingrid Lundberg⁷ and Maryam Dastmalchi⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ³Department of Pathology, Karolinska University Hospital,Pathology, Karolinska University Hospital., Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet. Rheumatology, Karolinska University Hospital Stockholm, Sweden. Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…
Abstract Number: 2238 • ACR Convergence 2022
Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles
Didem Saygin¹, Hanna Kim², Christian Douglas³, Brian Erman³, Jesse Wilkerson³, john mcgrath³, Chester Oddis⁴, Ingrid Lundberg⁵, Anthony Amato⁶, Ignacio Garcia-De La Torre⁷, Hector Chinoy⁸, David Fiorentino⁹, Lorinda Chung⁹, Yeong-Wook Song¹⁰, Katalin Danko¹¹, Frederick Miller¹², Nicola Ruperto¹³, Jiří Vencovský¹⁴, Rohit Aggarwal¹⁵ and Lisa G Rider¹², ¹University of Chicago, Chicago, IL, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Social and Scientific Systems, Inc., Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Harvard University, Boston, MA, ⁷Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ⁸The University of Manchester, Sale, United Kingdom, ⁹Stanford University, Stanford, CA, ¹⁰Seoul National University, Seoul, Republic of Korea, ¹¹*Deceased, Debrecen, Hungary, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
Abstract Number: 2262 • ACR Convergence 2022
Albumin-hitchhiking MMP13 siRNA Conjugate (siMMP13< (EG18L)2) for the Treatment of Rheumatic Disease
Juan Colazo¹, Ella Hoogenboezem¹, Fang Yu¹, Veeraj Shah¹, Justin Lo¹, Hongsik Cho², Karen Hasty², Leslie Crofford³ and Craig Duvall¹, ¹Department of Biomedical Engineering, Vanderbilt University, Nashville, Nashville, TN, ²Department of Orthopaedic Surgery and Biomedical Engineering, Memphis VA Medical Center, Memphis, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) decrease quality of life due to joint destruction, pain, and decreased function. Multiple joint osteoarthritis (MJOA) can occur…
Abstract Number: 2247 • ACR Convergence 2022
Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions
Shilpa Venkatachalam¹, William Benjamin Nowell², Shubhasree Banerjee³, Kelly Gavigan⁴, Laura Stradford², Jennifer Gordon⁵, Lisa Emerich⁶, Hope Sullivan⁷, Ashira Blazer⁸, Brittany Banbury⁹, Vandana Dronadula¹, Kimberly Weaver¹⁰, Angela Degrassi⁴, Peter Merkel³, Robert McBurney¹¹, Mike Kappelman¹⁰, Jeffrey Curtis¹² and Michael George³, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Vasculitis Foundation, Philadelphia, ⁶iConquerMS, Waltham, MA, ⁷Inflammatory Bowel Disease (IBD) Partners, Chapel Hill, NC, ⁸Hospital for Special Surgery, New York, NY, ⁹NYU Langone, Fort Lee, NJ, ¹⁰School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, ¹¹Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Compared to the general population, adults living with autoimmune disease are at nearly twice the risk of vaccine-preventable infections, making this a high priority…
Abstract Number: 2215 • ACR Convergence 2022
Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
Daniel Solomon¹, Jon Giles², Katherine Liao¹, Paul Ridker¹, Pamela Rist¹, Robert Glynn¹, Rachel Broderick³, Fengxin Lu¹, Meredith Murray¹, Kathleen Vanni¹, Leah Santacroce¹, Shady Abohashem⁴, Philip Robson⁵, Zahi Fayad⁶, Venkatesh Mani⁵, Ahmed Tawakol⁴ and Joan Bathon⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Columbia University, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Mount Sinai, New York, NY, ⁷Columbia University Medical Center, New York, NY
Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
Abstract Number: 2154 • ACR Convergence 2022
An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin
Elizabeth Bundschuh¹, Rebecca Fine², Miruna Carnaru³, Sanchit Kumar⁴, Francis Perry Wilson², Alyssa Williams¹, Shannon Teaw⁴, Ian Odell⁴ and Monique Hinchcliff⁵, ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Hartford Healthcare Medical Group, Rocky Hill, CT, ⁴Yale University School of Medicine, New Haven, CT, ⁵Yale School of Medicine, Westport, CT
Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, R. Hal Scofield², Kiely Grundahl¹, Lida Radfar², Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].